Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008 Sep 20;23(5):334–340. doi: 10.1007/s00380-008-1048-7

Early use of beta-blockers attenuates systemic inflammatory response and lung oxygenation impairment after distal type acute aortic dissection

Yusuke Jo 1, Toshihisa Anzai 1,✉, Yasuo Sugano 1, Kotaro Naito 1, Koji Ueno 1, Takashi Kohno 1, Tsutomu Yoshikawa 1, Satoshi Ogawa 1
PMCID: PMC7101827  PMID: 18810582

Abstract

We have reported that serum C-reactive protein (CRP) elevation is an independent predictor of lung oxygenation impairment (LOI) after distal type acute aortic dissection (AAD). Systemic activation of the inflammatory system after aortic injury may play a role in the development of LOI. The aim of this study is to clarify the effect of beta-blockers on systemic inflammation and the development of LOI after distal type AAD. A total of 49 patients, who were admitted with distal type AAD and treated conservatively, were examined. White blood cell (WBC) count, serum CRP level, and arterial blood gases were measured serially. Forty patients received beta-blocker treatment within 24 h of the onset, while 9 patients received no beta-blocker treatment. Maximum WBC count, maximum CRP level, lowest PaO2/FiO2 (P/F) ratio, and patient background were compared between the two groups. There was no difference between the groups according to age, sex, coronary risk factors, blood pressure, serum level of CRP, WBC count, and oxygenation index on admission. Beta-blocker treatment was associated with lower maximum WBC count (P = 0.0028) and lower maximum serum CRP level (P = 0.0004). The minimum P/F ratio was higher in patients with beta-blocker treatment than in those without (P = 0.0076). Multivariate analysis revealed that administration of a beta-blocker was an independent negative determinant of LOI (P/F ratio ≤200 mmHg). In conclusion, early use of beta-blockers prevented excessive inflammation and LOI after distal type AAD, suggesting a pleiotropic effect of beta-blockers on the inflammatory response after AAD.

Key words: Acute aortic dissection, Beta-blocker, Inflammation, Lung oxygenation impairment, C-reactive protein

References

  • 1.Hagan P.G., Nienaber C.A., Isselbacher E.M., Bruckman D., Karavite D.J., Russman P.L., Evangelista A., Fattori R., Suzuki T., Oh J.K., Moore A.G., Malouf J.F., Pape L.A., Gaca C., Sechtem U., Lenferink S., Deutsch H.J., Diedrichs H., Marcos y Robles J., Llovet A., Gilon D., Das S.K., Armstrong W.F., Deeb G.M., Eagle K.A. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000;283:897–903. doi: 10.1001/jama.283.7.897. [DOI] [PubMed] [Google Scholar]
  • 2.Suzuki T., Mehta R.H., Ince H., Nagai R., Sakomura Y., Weber F., Sumiyoshi T., Bossone E., Trimarchi S., Cooper J.V., Smith D.E., Isselbacher E.M., Eagle K.A., Nienaber C.A. Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD) Circulation. 2003;108(Suppl1):II312–II317. doi: 10.1161/01.cir.0000087386.07204.09. [DOI] [PubMed] [Google Scholar]
  • 3.Komukai K., Shibata T., Mochizuki S. C-reactive protein is related to impaired oxygenation in patients with acute aortic dissection. Int Heart J. 2005;46:795–799. doi: 10.1536/ihj.46.795. [DOI] [PubMed] [Google Scholar]
  • 4.Sugano Y., Anzai T., Yoshikawa T., Satoh T., Iwanaga S., Hayashi T., Maekawa Y., Shimizu H., Yozu R., Ogawa S. Serum Creactive protein elevation predicts poor clinical outcome in patients with distal type acute aortic dissection: association with the occurrence of oxygenation impairment. Int J Cardiol. 2005;102:39–45. doi: 10.1016/j.ijcard.2004.03.076. [DOI] [PubMed] [Google Scholar]
  • 5.Hasegawa Y., Ishikawa S., Ohtaki A., Otani Y., Takahashi T., Sato Y., Koyano T., Yamagishi T., Ohki S., Kanda T., Morishita Y. Impaired lung oxygenation in acute aortic dissection. J Cardiovasc Surg (Torino) 1999;40:191–195. [PubMed] [Google Scholar]
  • 6.Anzai T., Yoshikawa T., Takahashi T., Maekawa Y., Okabe T., Asakura Y., Satoh T., Mitamura H., Ogawa S. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology. 2003;99:47–53. doi: 10.1159/000068449. [DOI] [PubMed] [Google Scholar]
  • 7.Prabhu S.D., Chandrasekar B., Murray D.R., Freeman G.L. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101:2103–2109. doi: 10.1161/01.cir.101.17.2103. [DOI] [PubMed] [Google Scholar]
  • 8.Mayer B., Holmer S.R., Hengstenberg C., Lieb W., Pfeifer M., Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103:182–186. doi: 10.1016/j.ijcard.2004.08.053. [DOI] [PubMed] [Google Scholar]
  • 9.Song G., Hennessy M., Zhao Y.L., Li Q., Han W.D., Qi Y., Zhao W.N., Silke B., Barry M., Doyle R., Spiers J.P. Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304) Pharmacol Res. 2006;54:57–64. doi: 10.1016/j.phrs.2006.02.006. [DOI] [PubMed] [Google Scholar]
  • 10.Wikstrand J., Berglund G., Hedblad B., Hulthe J. Antiathero-sclerotic effects of beta-blockers. Am J Cardiol. 2003;91:25H–29H. doi: 10.1016/S0002-9149(03)00431-4. [DOI] [PubMed] [Google Scholar]
  • 11.Mason R.P., Kubant R., Jacob R.F., Walter M.F., Boychuk B., Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol. 2006;48:862–869. doi: 10.1097/01.fjc.0000238593.67191.e2. [DOI] [PubMed] [Google Scholar]
  • 12.DeBakey M.E., McCollum C.H., Crawford E.S., Morris G.C., Jr., Howell J., Noon G.P., Lawrie G. Dissection and dissecting aneurysms of the aorta: twenty-year follow-up of five hundred twenty-seven patients treated surgically. Surgery. 1982;92:1118–1134. [PubMed] [Google Scholar]
  • 13.Schillinger M., Domanovits H., Bayegan K., Holzenbein T., Grabenwoger M., Thoenissen J., Roggla M., Mullner M. C-reactive protein and mortality in patients with acute aortic disease. Intensive Care Med. 2002;28:740–745. doi: 10.1007/s00134-002-1299-1. [DOI] [PubMed] [Google Scholar]
  • 14.Ishii T., Asuwa N. Collagen and elastin degradation by matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in aortic dissection. Hum Pathol. 2000;31:640–646. doi: 10.1053/hupa.2000.7642. [DOI] [PubMed] [Google Scholar]
  • 15.Muller B.T., Modlich O., Prisack H.B., Bojar H., Schipke J.D., Goecke T., Feindt P., Petzold T., Gams E., Muller W., Hort W., Sandmann W. Gene expression profiles in the acutely dissected human aorta. Eur J Vasc Endovasc Surg. 2002;24:356–364. doi: 10.1053/ejvs.2002.1731. [DOI] [PubMed] [Google Scholar]
  • 16.Sakuta A., Kimura F., Aoka Y., Aomi S., Hagiwara N., Kasanuki H. Delayed enhancement on computed tomography in abdominal aortic aneurysm wall. Heart Vessels. 2007;22:79–87. doi: 10.1007/s00380-006-0943-z. [DOI] [PubMed] [Google Scholar]
  • 17.Pararajasingam R., Nicholson M.L., Bell P.R., Sayers R.D. Noncardiogenic pulmonary oedema in vascular surgery. Eur J Vasc Endovasc Surg. 1999;17:93–105. doi: 10.1053/ejvs.1998.0750. [DOI] [PubMed] [Google Scholar]
  • 18.Furusawa T., Tsukioka K., Fukui D., Sakaguchi M., Seto T., Terasaki T., Wada Y., Amano J. The effects of a neutrophil elastase inhibitor on the postoperative respiratory failure of acute aortic dissection. Thorac Cardiovasc Surg. 2006;54:404–407. doi: 10.1055/s-2006-924195. [DOI] [PubMed] [Google Scholar]
  • 19.Munakata M., Itaya H., Daitoku K., Ono Y. Remarkable improvement of hemodynamics by continuous hemodiafiltration in patients after operation for thoracic aortic dissection. Ann Thorac Cardiovasc Surg. 2005;11:277–280. [PubMed] [Google Scholar]
  • 20.Takahashi T., Anzai T., Yoshikawa T., Maekawa Y., Asakura Y., Satoh T., Mitamura H., Ogawa S. Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction — role of neurohormones and cytokines. Int J Cardiol. 2003;88:257–265. doi: 10.1016/S0167-5273(02)00416-3. [DOI] [PubMed] [Google Scholar]
  • 21.Murray D.R., Prabhu S.D., Chandrasekar B. Circulation. 2000;101:2338–2341. doi: 10.1161/01.cir.101.20.2338. [DOI] [PubMed] [Google Scholar]
  • 22.Bürger A., Benicke M., Deten A., Zimmer H.G. Am J Physiol Heart Circ Physiol. 2001;281:H14–H21. doi: 10.1152/ajpheart.2001.281.1.H14. [DOI] [PubMed] [Google Scholar]
  • 23.Fratta Pasini A., Garbin U., Nava M.C., Stranieri C., Davoli A., Sawamura T., Lo Cascio V., Cominacini L. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589–596. doi: 10.1097/01.hjh.0000160216.86597.ff. [DOI] [PubMed] [Google Scholar]
  • 24.Spallarossa P., Garibaldi S., Altieri P., Fabbi P., Manca V., Nasti S., Rossettin P., Ghigliotti G., Ballestrero A., Patrone F., Barsotti A., Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37:837–846. doi: 10.1016/j.yjmcc.2004.05.024. [DOI] [PubMed] [Google Scholar]
  • 25.Kalinowski L., Dobrucki L.W., Szczepanska-Konkel M., Jankowski M., Martyniec L., Angielski S., Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747–2752. doi: 10.1161/01.CIR.0000066912.58385.DE. [DOI] [PubMed] [Google Scholar]
  • 26.Ruffolo R.R., Jr, Feuerstein G.Z. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther. 1997;11(Suppl1):247–256. doi: 10.1023/A:1007735729121. [DOI] [PubMed] [Google Scholar]
  • 27.Yue T.L., Wang X., Gu J.L., Ruffolo R.R., Jr, Feuerstein G.Z. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol. 1995;294:585–591. doi: 10.1016/0014-2999(95)00596-X. [DOI] [PubMed] [Google Scholar]
  • 28.Feuerstein G.Z., Fisher M., Nunnart J., Ruffolo R.R., Jr Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat. Pharmacology. 1997;54:24–32. doi: 10.1159/000139466. [DOI] [PubMed] [Google Scholar]
  • 29.van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 1996;97:713–719. doi: 10.1172/JCI118469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Panina-Bordignon P., Mazzeo D., Lucia P.D., D’Ambrosio D., Lang R., Fabbri L., Self C., Sinigaglia F. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest. 1997;100:1513–1519. doi: 10.1172/JCI119674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Severn A., Rapson N.T., Hunter C.A., Liew F.Y. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol. 1992;148:3441–3445. [PubMed] [Google Scholar]
  • 32.Viora M., Straface E., Di Genova G., Fattorossi A., Rivabene R., Camponeschi B., Masella R., Malorni W. Oxidized low density lipoproteins impair peripheral blood mononuclear cell proliferation and cytokine production. Biochem Biophys Res Commun. 1997;232:359–363. doi: 10.1006/bbrc.1997.6294. [DOI] [PubMed] [Google Scholar]
  • 33.Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., Lysko K.A., Davis L.L., Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92–98. [PubMed] [Google Scholar]
  • 34.Nishio R., Shioi T., Sasayama S., Matsumori A. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol. 2003;41:340–345. doi: 10.1016/S0735-1097(02)02711-0. [DOI] [PubMed] [Google Scholar]

Articles from Heart and Vessels are provided here courtesy of Nature Publishing Group

RESOURCES